Floatz logo

SODIUM SULFATE, ANHYDROUS

Epithelial Ovarian Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
73/ 100

Competitive context

244 Active assets in the Epithelial Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

SODIUM SULFATE, ANHYDROUS is also rated in:

Relapsing Remitting Multiple SclerosisDormant
CCC
Indicative ·
53 / 100
View asset →
acute kidney injuryDormant
CC
Indicative ·
46 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →